Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities

Thrombosis and Haemostasis

Volumn 99, Issue 3, 2008, Pages 539-545

  Fonseca, Roberto J C ^a   Oliveira, Stephan Nicollas M C G ^a   Melo, Fábio R ^a   Pereira, Maria G ^b   Benevides, Norma M B ^b   Mourão, Paulo A S ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Anticoagulant; Antithrombotic; Marine red alga; Sulfated galactans; Sulfation pattern

Indexed keywords

BOTRYOCLADIA OCCIDENTALIS EXTRACT; GALACTAN; GELIDIUM CRINALE EXTRACT; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ADULT; ANIMAL TISSUE; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; BODY WEIGHT; DOSE RESPONSE; DRUG ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; SULFATION; VEIN THROMBOSIS;

ALGAE, RED; ANIMALS; ANTICOAGULANTS; BLEEDING TIME; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XIIA; FEMALE; FIBRINOLYTIC AGENTS; GALACTANS; HEMORRHAGE; HEPARIN; HUMANS; MALE; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PLATELET AGGREGATION; RATS; RATS, WISTAR; SULFATES; THROMBOSIS; VENOUS THROMBOSIS;

EID: 42249096311     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-10-0603     Document Type: Article

References (25)

1. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: 14-18.
2. White RH, Zhou H, Romano P, et al. Changes in plasma warfarin levels and variations in steady-state prothrombin times. Clin Pharmcol Ther 1995; 58: 588-593.
3. Merlini PA, Ardissino D, Bauer KA, et al. Persistant thrombin generation during heparin therapy in patients with acute coronary syndromes. Aterioscler Thromb Vasc Biol 1997; 17: 1325-1330.
4. Fonseca RJC, Mourão PAS. Fucosylated chondroitin sulfate as a new antithrombotic agent. Thromb Haemost 2006; 96: 822-829.
5. Pereira MS, Melo FR, Mourão PAS. Is there a correlation between structure and anticoagulant action of sulfated galactans and sulfated fucans? Glycobiology 2002; 12: 573-580.
6. Farias WRL, Valente AP, Pereira MS, et al. Structure and anticoagulant activity of sulfated galactans - Isolation of a unique sulfated galactan from the red algae Botryocladia occidentalis and comparison of its anticoagulant action with that of sulfated galactans from invertebrates. J Biol Chem 2000; 275: 29299-29307.
7. Mourão PA. Use of sulfated fucans as anticoagulant and antithrombotic agents: future perspectives. Curr Pharm Des 2004; 10: 967-981.
8. Pereira MP, Benevides NMB, Melo MRS, et al. Structure and anticoagulant activity of a sulfated galactan from the red alga, Gelidium crinale. Is there a specific structural requirement for the anticoagulant action? Carbohydr Res 2005; 340: 2015-2023.
9. Farndale RW, Buttle DJ, Barret AJ. Improved quantitation and discrimination of sulfated glycosaminoglycans by use of dimethylmethylene blue. Biochem Biophys Acta 1986; 883: 173-177
10. Wessler S, Reimer SM, Sheps MC. Biological assay of a thrombosis inducing activity in human serum. J Appl Physiol 1959; 14: 943-946.
11. Eitzman DT, Westrick RJ, Nabel EG, et al. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 2000; 95: 577-580.
12. Herbert JM, Bernat A, Maffrand JP. Importance of platelets in experimental venous thrombosis in rats. Blood 1992; 80: 2281-2286.
13. Zhuo R, Miller R, Bussard KM, et al. Procoagulant stimulus processing by the intrinsic pathway of blood plasma coagulation. Biomaterials 2005; 26: 2965-2973.
14. American Heart Association 2002. Heart and Stroke. Statistical update.
15. Friedman RJ. Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty. J Am Acad Orthop Surg 2007 15: 148-155.
16. Mourão PAS, Pereira MS. Searching for alternatives to heparin. Trends Cardiovasc Med 1999; 9: 225-232.
17. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-10370.
18. Dahlback B. Blood coagulation. Lancet 2000 ; 355: 1627-1632
19. Renné T, Pozgajová M, Grüner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 18: 271-281.
20. Yarovaya GA, Blokhina TB, Neshkova EA. Contact system. New concepts on activation mechanisms and bioregulatory functions. Biochemistry 2002; 67: 16-29.
21. Blezer R, Fouache B, Willems GM, et al. Activation of blood coagulation at heparin-coated surfaces. J Biomed Mater Res 1997; 37: 108-113.
22. et al. Improved coagulation in bleeding disorders by non-anticoagulant sulfated polysaccharides (NASP). Thromb Haemost 2006; 95: 68-76.
23. Heit JA. Risk factors for venous thromboembolism. Clin Chest Med 2003; 24: 1-12.
24. Kurabayashi H, Tamura J, Naruse T, et al. Possible existence of platelet activation before the onset of cerebral infarction. Atherosclerosis 2000; 153: 203-207.
25. Nylander S, Mattsson C. Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action. Blood Coagul Fibrinolysis 2003; 14: 159-167.